Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci098 in Thyroid Eye Disease
NCT06569758Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GenSci098 in thyroid eye disease (TED), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Incidence and severity of adverse events at 281 days. Started Sep 2024; status: recruiting.
02
Drugs
GenSci098
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06569758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569758.